-$0.10 EPS Expected for Vericel Corp (VCEL) This Quarter
Equities research analysts expect Vericel Corp (NASDAQ:VCEL) to post earnings per share of ($0.10) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Vericel’s earnings. Vericel posted earnings per share of ($0.14) in the same quarter last year, which suggests a positive year-over-year growth rate of 28.6%. The company is scheduled to issue its next quarterly earnings report on Friday, March 9th.
According to Zacks, analysts expect that Vericel will report full year earnings of ($0.60) per share for the current fiscal year, with EPS estimates ranging from ($0.64) to ($0.56). For the next year, analysts anticipate that the company will post earnings of ($0.36) per share, with EPS estimates ranging from ($0.48) to ($0.24). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Vericel.
Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.01. The company had revenue of $14.26 million during the quarter. Vericel had a negative net margin of 45.11% and a negative return on equity of 265.45%.
Shares of Vericel (VCEL) traded up $0.25 during trading on Wednesday, reaching $5.15. 663,716 shares of the company’s stock were exchanged, compared to its average volume of 470,498. The company has a current ratio of 2.50, a quick ratio of 2.22 and a debt-to-equity ratio of 0.44. Vericel has a fifty-two week low of $2.25 and a fifty-two week high of $6.30.
Institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp increased its position in Vericel by 13.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,202 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 4,523 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Vericel in the 3rd quarter worth about $235,000. JPMorgan Chase & Co. purchased a new stake in shares of Vericel in the 3rd quarter worth about $328,000. EAM Investors LLC purchased a new stake in shares of Vericel in the 3rd quarter worth about $943,000. Finally, Perkins Capital Management Inc. grew its position in shares of Vericel by 118.4% in the 3rd quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock worth $3,376,000 after buying an additional 305,000 shares during the period. 33.12% of the stock is currently owned by institutional investors and hedge funds.
Vericel Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.